1. Report Overview

1.1 The Companion Diagnostics Market Overview

1.2 Companion Diagnostics Market Segmentation

1.3 Why You Should Read This Report

1.4 How This Report Delivers

1.5 Key Questions Answered by This Analytical Report

1.6 Who is This Report For?

1.7 Methodology

1.8 Frequently Asked Questions (FAQ)

1.9 Associated Reports

1.10 About Visiongain

2. Introduction to Companion Diagnostics

2.1 The Foundation of Personalised Medicine

2.2 Personalised Medicine: Changing the Patient Treatment Paradigm

2.3 In Vitro Diagnostic (IVD) Tests

2.3.1 Companion Diagnostics: A Type of IVD

2.3.2 Differences between Companion Diagnostics and Theranostics

2.3.3 Biomarkers to Companion Diagnostics

2.3.4 Genomic Biomarkers

2.3.5 Genomic Oncology Biomarkers

2.4 Regulations in the Companion Diagnostics Market

2.4.1 FDA's Final Guidance on Companion Diagnostics

2.4.2 LDTs: A Changing Landscape

2.5 Encouraging the Contemporaneous Development of Companion Diagnostics

3. The World Companion Diagnostics Market, 2017-2028

3.1 Scope and Limitations

3.2 The Global Companion Diagnostics Market, 2016 and 2017

3.3 The Global Companion Diagnostics Market Sales Forecast, 2017-2028

3.4 Companion Diagnostics: Growth Outpacing the Rest of the IVD Market

3.5 Companion Diagnostics: Increasing Market Share of the IVD Market

3.6 The Companion Diagnostics Market by Submarket, 2017

3.7 Theranostics: Fastest Growing Segment of the CDx Market

3.8 Changing Market Shares of the Leading Companion Diagnostics Submarkets, 2017-2028

4. Leading National Markets for Companion Diagnostics, 2017-2028

4.1 The Leading National Markets for Companion Diagnostics: Led by 3 Dominant Markets in 2017

4.2 The Leading National Markets for Companion Diagnostics Sales Forecast, 2017-2028

4.2.1 Changing Market Shares of Leading National Markets, 2017-2028

4.3 The US Companion Diagnostics Market Sales Forecast, 2017-2028

4.3.1 The US Will Continue to Dominate the Market

4.4 The EU5 Companion Diagnostics Sales Market, 2017

4.4.1 The EU5 Companion Diagnostics Market Sales Forecast, 2017-2028

4.4.2 Changing Market Shares of the EU5 Companion Diagnostics Market

4.4.3 The German Companion Diagnostics Market Sales Forecast 2017-2028

4.4.4 The French Companion Diagnostics Market Sales Forecast, 2017-2028

4.4.5 The Italian Companion Diagnostics Market Sales Forecast, 2017 2028

4.4.6 The Spanish Companion Diagnostics Market Sales Forecast, 2017-2028

4.4.7 The UK Companion Diagnostics Market Sales Forecast, 2017-2028

4.5 The Japanese Companion Diagnostics Market Sales Forecast, 2017-2028

4.5.1 Japan’s Medical Technology Regulatory Process Reducing Time to Market

4.6 The Chinese Companion Diagnostics Market Sales Forecast, 2017-2028

4.6.1 Cancer Rates will Drive Adoption of Companion Diagnostic Tests

4.7 The Indian Companion Diagnostics Market Sales Forecast, 2017-2028

4.8 The Brazilian Companion Diagnostics Market Sales Forecast, 2017-2028

4.9 The Russian Companion Diagnostics Market Sales Forecast, 2017-2028

4.10 The South Korean Companion Diagnostics Market Sales Forecast, 2017-2028

4.11 The Rest of the World Companion Diagnostics Market Sales Forecast, 2017-2028

5. The Companion Diagnostics Market: Marketed Products and Pipeline Partnerships

5.1 Biomarkers: At the Forefront of Companion Diagnostics Development

5.2 US FDA Approved Companion Diagnostic Tests, 2016

5.3 Oncology Continues to Dominate the R&D Pipeline of Companion Diagnostics

5.4 Expensive Cancer Therapies Encourages the Development of CDx

5.5 Companion Diagnostic/Pharma Partnerships, 2013-2014

6. Business Models and Stakeholders in the Companion Diagnostics Market

6.1 Business Models for the Development of Companion Diagnostics

6.1.1 The Partnership Model is the Most Practiced Method

6.1.2 The Stand-Alone Model: Licensing an IP

6.1.3 The One Stop Shop Model: An Approach by Big Pharma

6.1.4 Using Contract Diagnostics Organisations (CDO): An Emerging Trend

6.2 Factors Driving Companies to Enter the Companion Diagnostics Market

6.3 Stakeholders Influencing the Companion Diagnostics Market

6.3.1 Pharmaceutical Companies and Diagnostic Manufacturers

6.3.2 Regulatory Authorities

6.3.3 Testing Laboratories

6.3.4 Physicians and Patients

6.3.5 Payers

6.4 Companion Diagnostics Competitive Landscape, 2017

7. Leading Companies in the Companion Diagnostics Market 2017

7.1 Roche: Global Diagnostics Leader

7.1.1 Ventana Medical Systems (Roche)

7.1.2 Sales and Recent Performance Analysis, 2016

7.1.3 Roche Diagnostics by Region, 2016

7.1.4 Roche: Growing Diagnostic Portfolio

7.1.5 Approval of Ventana and Cobas EGFR Mutation Test V2

7.1.6 Roche’s Portfolio of Companion Diagnostic Project Pipeline and Marketed Companion Diagnostics, 2017

7.1.7 Ventana Companion Diagnostics: Robust New Prototype Assays

7.1.8 Recent Companion Diagnostic External Collaborations, 2014-2017

7.1.8.1 Roche/Ariosa Diagnostics and Signature Diagnostics

7.1.8.2 Loxo Oncology/ Roche: Larotrectinib Pan-TRK IHC Companion Diagnostic

7.1.8.3 CAPP Medical/ Roche: Development for Diagnostic Operating Segment

7.1.8.4 GENEWEAVE and Kapa Acquisitions Help Cement Roche’s Position as the Market Leader

7.1.8.5 Foundation Medicine/Roche

7.1.8.6 MedImmune (AstraZeneca)/Ventana: Assay for NSCLC Targeted Clinical Trials

7.1.8.7 Merck/Ventana: CDx for an Undisclosed Target

7.1.8.8 AstraZeneca/Roche: CDx to Support Target Drug AZD9291

7.1.8.9 Boehringer Ingelheim/Roche

7.1.8.10 ImmunoGen/ Ventana

7.2 Qiagen N.V.: Leading CDx Collaborator with Pharmaceutical Companies

7.2.1 Sales and Recent Performance Analysis, 2012-2016

7.2.2 Qiagen Sales by Region

7.2.3 Qiagen’s Portfolio of Marketed Companion Diagnostics, 2016

7.2.4 Companion Diagnostics Collaboration Agreements with Pharma, 2016

7.2.4.1 Collaboration with Therawis Diagnostics

7.2.4.2 Collaboration with HTG Molecular Diagnostics

7.2.4.3 Collaboration with Array BioPharma

7.2.4.4 Collaboration with Singulex

7.2.4.5 Strategic Acquisitions

7.3 Abbott Molecular: An Established Competitor

7.3.1 Sales and Recent Performance Analysis, 2014-2016

7.3.2 Abbott Molecular: Expansive Oncology Biomarker Pipeline

7.3.3 Recent Collaborations

7.3.3.1 Collaboration with Celgene and Agios

7.3.3.2 Collaboration with AstraZeneca

7.3.3.3 Collaborative Efforts with Idera

7.4 Agilent Technologies (Dako)

7.4.1 Life Sciences and Diagnostics Business

7.4.2 Agilent Life Sciences and Diagnostics, Sales and Recent Performance Analysis, 2016

7.4.3 Agilent: Next Generation Sequencing Platforms

7.4.4 Recent Companion Diagnostic Approvals

7.4.4.1 Expanded FDA Approval for the Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Gastric or Gastroesophageal Junction (GEJ) Cancer

7.4.4.2 Agilent/ Bristol- Myers Squibb’s: Companion Diagnostic Approvals

7.4.4.3 Agilent/Pfizer/Merck: An Ongoing Collaboration

7.4.5 Strategic Acquisitions

7.4.5.1 Acquisition of i-Lab Solutions

7.4.5.2 Acquisition of Multiplicom

7.5 Myriad Genetics

7.5.1 Acquisition of Myriad RBM: Increases the Company’s Market Share of Companion Diagnostics

7.5.2 Companion Diagnostic Service Offerings

7.5.3 Sales and Recent Performance Analysis, 2016

7.5.3.1 myRisk: Next Generation Hereditary Cancer Testing

7.5.4 Myriad Genetics Recent Collaborations

7.5.4.1 Myriad/BeiGene: Collaboration Agreement

7.5.4.2 Myriad/AstraZeneca: Complementary Diagnostic FDA Approvals

7.5.4.3 Acquisition of /Sividone Diagnostics

7.5.4.4 Acquisition of Assurex Health

7.5.4.5 Collaboration with AbbVie

7.6 BioMérieux

7.6.1 Sales and Recent Performance Analysis, 2016

7.6.2 Sales by Region, 2016

7.6.3 Sales by Technology, 2016

7.6.4 Companion Diagnostics: Recent M&A Activity & Collaboration

7.6.4.1 Strategic Acquisitions

7.6.4.2 Collaboration with Banyan Biomarkers

7.6.4.3 Agreement with Astute Medical to Distribute Nephrocheck

7.6.4.4 Mergers, Acquisitions and Collaborations

7.6.5 bioTheranostics: Subsidiary for Oncology Diagnostics

7.7 Thermo Fisher Scientific

7.7.1 Sales and Recent Performance Analysis, 2014-2016

7.7.1.1 Thermo Fisher Scientific Sales by Region, 2016

7.7.2 Recent Collaborations and Acquisitions

7.7.2.1 Thermo Fisher Scientific/Seegene-FDA Clearances

7.7.2.2 Thermo Fisher Scientific/University Hospital Basel

7.7.2.3 Acquisition of Alfa Aesar

7.7.2.4 Affymetrix: Thermo Fisher’s Next Target

7.7.2.5 Thermo Fisher Scientific Collaboration with Pfizer and Novartis to Offer NGS-Based Companion Test for NSCLC

8. Qualitative Analysis of the Companion Diagnostics Market, 2017-2028

8.1 SWOT Analysis of the Companion Diagnostics Market

8.2 Strengths

8.2.1 A CDx Strategy Decreases the Length of Approval Process

8.2.2 Premium Prices for Companion Diagnostics

8.2.3 A CDx Development Strategy Can Generate More Effective Drugs

8.2.4 Therapeutics Tied with CDx can have Safer Profiles

8.2.5 Reducing the Cost of Healthcare

8.2.6 Increased Regulatory Scrutiny on Marketed Drugs

8.2.7 Targeted Therapies Will Drive the CDx Market

8.3 Weaknesses

8.3.1 Reimbursement Challenges

8.3.2 Lack of Clear Regulatory Guidelines

8.3.3 Capital Intensity is High

8.4 Opportunities

8.4.1 Fast-growing Emerging Markets

8.4.2 Next Generation Sequencing

8.4.3 Many New CDx/ Pharma Company Partnerships

8.5 Threats

8.5.1 Complex Business Models and Business Partnerships

8.5.2 Medical Device Excise Tax

8.6 Porter’s Five Forces Analysis of the Companion Diagnostics Market

8.6.1 Rivalry Among Competitors [High]

8.6.2 Power of Suppliers [High]

8.6.3 Power of Buyers [Medium]

8.6.4 Threat of New Entrants [Medium]

8.6.5 Threat of Substitutes [High]

9. Conclusions

9.1 Overview

9.2 Theranostics: A Fast Growing Market

9.3 Leading Companion Diagnostic Companies

9.4 Pharmaceutical/Diagnostic Partnership Model

9.5 Oncology is the Leading Therapy Area Driving Companion Diagnostics

9.6 Commercial Drivers of the Companion Diagnostics Market

9.7 Commercial Restraints of the Companion Diagnostics Market

9.8 Concluding Remarks

10. Glossary

Associated Reports

 Visiongion Report Sales Order Form

Appendix A

About Visiongain

Appendix B

Visiongain Report Evaluation Form

Table of Tables

Table 1.1 The CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2017-2023

Table 1.2 The CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2023-2028

Table 2.1 Examples of Clinically Relevant Cancer Biomarkers, 2016

Table 3.1 The World IVD Market: Revenue ($bn) and Market Share (%) by Segment, 2017

Table 3.2 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023

Table 3.3 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028

Table 3.4 The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023

Table 3.5 The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028

Table 3.6 CDx Market Share (%) in the IVD Market, 2017, 2023, 2028

Table 3.7 The World Companion Diagnostics Market: Revenue ($bn) and Market Share (%) by Submarket, 2017

Table 3.8 The World Companion Diagnostics Market by Submarket: Revenue ($bn), AGR (%) and CAGR (%), by Submarket, 2017-2023

Table 3.9 The World Companion Diagnostics Market by Submarket: Revenue ($bn), AGR (%) and CAGR (%), by Submarket, 2023-2028

Table 3.10 Revenue ($bn) and Market Share (%) of Submarkets in the CDx Market, 2017, 2023, 2028

Table 4.1 The Leading National Markets for CDx: Sales ($m), Market Share (%), 2017

Table 4.2 The Leading National Companion Diagnostics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2023

Table 4.3 The Leading National Companion Diagnostics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2023-2028

Table 4.4 Revenue ($bn) and Market Share (%) of the National Markets in the CDx Market, 2017, 2023, 2027

Table 4.5 The US CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2017-2023

Table 4.6 The US CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2023-2028

Table 4.7 The EU5 CDx Market Forecast: Revenue ($bn) and Market Share (%), 2017

Table 4.8 The EU5 Companion Diagnostic National Market Forecasts: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023

Table 4.9 The EU5 Companion Diagnostic National Market Forecasts: Revenues ($bn), AGR (%) and CAGR (%), 2023-2028

Table 4.10 Market Share (%) of Each EU5 Region in the CDx Market, 2017, 2023, 2027

Table 4.11 The German CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 4.12 The German CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 4.13 The French CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023

Table 4.14 The French CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028

Table 4.15 The Italian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023

Table 4.16 The Italian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028

Table 4.17 The Spanish CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023

Table 4.18 The Spanish CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028

Table 4.19 The UK CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023

Table 4.20 The UK CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028

Table 4.21 The Japanese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2017-2023

Table 4.22 The Japanese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2023-2028

Table 4.23 The Chinese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023

Table 4.24 The Chinese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028

Table 4.25 The Indian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023

Table 4.26 The Indian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028

Table 4.27 The Brazilian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023

Table 4.28 The Brazilian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2027-2028

Table 4.29 The Russian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023

Table 4.30 The Russian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028

Table 4.31 The South Korean CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023

Table 4.32 The South Korean CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028

Table 4.33 The Rest of the World CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023

Table 4.34 The Rest of the World CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028

Table 5.1 List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018

Table 5.2 (Cont’d) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018

Table 5.3 (Cont’d) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018

Table 5.4 (Cont’d) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018

Table 5.5 (Cont’d) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018

Table 5.6 List of Cleared or Approved Companion Diagnostic Devices and Their Complementary Therapeutic Drug, 2015-2017

Table 5.7 List of CDx Diagnostic/Pharma Partnerships, 2015-2017

Table 6.1 List of Companies in the Companion Diagnostics Market, 2017

Table 6.2 (Cont’d) List of Companies in the Companion Diagnostics Market, 2017

Table 7.1 Roche Diagnostics: Revenue ($bn) and Revenue Share (%) by Business Area, 2016

Table 7.2 Roche Diagnostics: Revenue ($bn), Revenue Shares (%) by Region, 2016

Table 7.3 Roche: Instruments/devices planned for 2017

Table 7.4 Roche: Tests/Assays planned for 2017

Table 7.5 Roche Diagnostics: List of Marketed Companion Diagnostics, 2017

Table 7.6 Qiagen: Revenue ($bn), Net Income ($bn) and Profit Margin, 2012-2016

Table 7.7 Qiagen: Revenue ($m), Revenue Share (%) by Geography, 2014-2016

Table 7.8 Qiagen: Marketed Molecular Diagnostic Products, 2016

Table 7.9 Qiagen’s Molecular Diagnostics by Therapeutic Area, 2016

Table 7.10 Abbott: Revenue ($bn) by Segment, 2014-2016

Table 7.11 Abbott Molecular: Biomarker Pipeline, 2017

Table 7.12 Agilent Technologies: Revenue ($bn) by Business Segment 2014-2016

Table 7.13 Myriad Genetics: Biomarker Product Portfolio, 2016

Table 7.14 Myriad Genetics: Revenue ($bn) by Segment, FY ended June 2015- FY ended June 2017

Table 7.15 bioMérieux : Revenue (€bn), ($bn) and AGR (%), 2012-2016

Table 7.16 bioMérieux: Revenue Share (%) by Technology, 2016

Table 7.17 Thermo Fisher Scientific: Revenue ($bn) and Market Share (%)

Table 7.18 Thermo Fisher Scientific: Revenue ($bn), Revenue Share (%) by Geography, 2016

Table 8.1 SWOT Analysis of the Companion Diagnostics Market, 2017-2028

Table 9.1 Theranostics and Other In Vitro Diagnostics: Global Sales Forecast ($bn), 2017, 2023 and 2028

Table of Figures

Figure 1.1 Companion Diagnostics: Overview of Submarkets

Figure 2.1 Development of Biomarkers into Companion Diagnostics, 2018

Figure 3.1 The World IVD Market: Market Share (%) in the IVD Market, 2017

Figure 3.2 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Figure 3.3 The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Figure 3.4 The World CDx Market Share (%) in the IVD Market, 2023

Figure 3.5 The World CDx Market Share (%) in the IVD Market, 2028

Figure 3.6 The World Companion Diagnostics Market: Market Share (%) by Submarket, 2017

Figure 3.7 The World CDx Market by Submarket: Revenue ($bn) and AGR (%) 2017-2028

Figure 3.8 The World CDx Market Share (%) in the IVD Market, 2023

Figure 3.9 The World CDx Market Share (%) in the IVD Market, 2028

Figure 4.1 The Leading National Markets for CDx by Sales ($bn), 2017

Figure 4.2 The Leading National Markets for CDx by Market Share (%), 2017

Figure 4.3 The Leading National Markets for CDx by Market Share (%), 2023

Figure 4.4 The Leading National Markets for CDx by Market Share (%), 2027

Figure 4.5 The US CDx Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 4.6 The EU5 Leading National Markets for CDx by Revenue ($bn), 2017

Figure 4.7 The EU5 Leading National Markets for CDx by Market Share (%), 2017

Figure 4.8 The EU5 National Markets for CDx by Market Share (%), 2023

Figure 4.9 The EU5 National Markets for CDx by Market Share (%), 2028

Figure 4.10 The German CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028

Figure 4.11 The French CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028

Figure 4.12 The Italian CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028

Figure 4.13 The Spanish CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028

Figure 4.14 The UK CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028

Figure 4.15 The Japanese CDx Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 4.16 The Chinese CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028

Figure 4.17 The Indian CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028

Figure 4.18 The Brazilian CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028

Figure 4.19 The Russian CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028

Figure 4.20 The South Korean CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028

Figure 4.21 The Rest of the World CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028

Figure 6.1 Current Business Models for the Development of Companion Diagnostics, 2017

Figure 6.2 Stakeholders in the Companion Diagnostics Market, 2017

Figure 7.1 Roche Diagnostics: Revenues ($bn) by Business Area, 2016

Figure 7.2 Roche Diagnostics: Revenue Share (%) by Business Area, 2016

Figure 7.3 Roche Diagnostics: Revenue Share (%) by Geography, 2016

Figure 7.4 Qiagen: Revenue ($bn) and Net Income ($bn), 2012-2016

Figure 7.5 Qiagen: Revenue Share (%) by Geography, 2016

Figure 7.6 Abbott Laboratories: Historical Revenue ($bn), 2013-2016

Figure 7.7 Abbott Laboratories: Revenue Share (%) by Business Sector, 2016

Figure 7.8 Agilent Technologies: Revenue ($bn) by Business Segment 2014-2016

Figure 7.9 Myriad Genetics: Segment Share (%), 2016

Figure 7.10 bioMérieux: Revenue ($bn) and AGR (%), 2012-2016

Figure 7.11 bioMérieux: Revenue by Region (%), 2016

Figure 7.12 bioMérieux: Revenue Share (%) by Technology, 2015

Figure 7.13 Thermo Fisher Scientific: Revenue Sales (%) by Business Sector, 2016

Figure 7.14 Thermo Fisher Scientific: Revenue Share (%) by Geography, 2016

Figure 8.1 Drivers and Restraints in the Companion Diagnostics Market, 2017-2028

Figure 8.2 Porter’s Five Analysis of the Companion Diagnostics Market, 2017-2028

Figure 9.1 Theranostics and Other In Vitro Diagnostics: World Sales Forecast ($bn), 2017, 2023 and 2028